In vitro evaluation of flavopiridol, a novel cell cycle inhibitor, in bladder cancer View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

1999-05

AUTHORS

Mark Chien, Mary Astumian, David Liebowitz, Carrie Rinker-Schaeffer, Walter M. Stadler

ABSTRACT

PURPOSE: To determine the in vitro effects of flavopiridol on bladder cancer cell lines, immortalized urothelial cell lines, and normal urothelial cells well characterized for defects in p53, pRb, and p16. METHODS: Growth inhibition was assessed via an MTT assay and apoptosis via DAPI nuclear staining. Cell cycle analysis was performed via propidium iodide staining and fluorescent activated cell sorting (FACS). Multidrug-resistant cells were generated by continuous exposure to doxorubicin. RESULTS: Growth inhibition was not correlated with inactivation of p53, pRb, or p16. All cells experienced G2/M arrest within 24 h of flavopiridol exposure. Modest apoptosis was observed but required 72 h of continuous drug exposure to become evident. There was no obvious synergistic or antagonistic toxicity when flavopiridol was combined with radiotherapy or cisplatin dosed at the IC50 despite the observation that radiotherapy and flavopiridol led to more profound G2/M arrest than either agent alone. Doxorubicin-resistant cells, demonstrated to overexpress the MDR1 multi-drug-resistance protein were equally as sensitive to flavopiridol as the parental cells. CONCLUSIONS: Flavopiridol is a novel cell cycle inhibitor that may be a useful agent in bladder cancers with tumor suppressor gene alterations and/or multidrug resistance. More... »

PAGES

81-87

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s002800050948

DOI

http://dx.doi.org/10.1007/s002800050948

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1011712647

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/10367753


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/0601", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Biochemistry and Cell Biology", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/06", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Biological Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antineoplastic Agents", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Apoptosis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Cell Cycle", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Cell Division", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Cell Line", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Cisplatin", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Combined Modality Therapy", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Drug Resistance, Multiple", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Flavonoids", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Genes, Tumor Suppressor", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Piperidines", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Radiotherapy", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Tumor Cells, Cultured", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Urinary Bladder Neoplasms", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Urothelium", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "name": [
            "Section of Urology, University of Chicago, Chicago, IL, USA, US"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Chien", 
        "givenName": "Mark", 
        "id": "sg:person.01167505012.73", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01167505012.73"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "Section of Urology, University of Chicago, Chicago, IL, USA, US"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Astumian", 
        "givenName": "Mary", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "Section of Hematology/Oncology, University of Chicago, 5841\u2009S. Maryland, MC2115, Chicago, IL 60637, USA e-mail: wmstadle@mcis.bsd.uchicago.edu Tel.: +1-773-702-4150; Fax: +1-773-702-3163, US"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Liebowitz", 
        "givenName": "David", 
        "id": "sg:person.01106365337.15", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01106365337.15"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "Section of Hematology/Oncology, University of Chicago, 5841\u2009S. Maryland, MC2115, Chicago, IL 60637, USA e-mail: wmstadle@mcis.bsd.uchicago.edu Tel.: +1-773-702-4150; Fax: +1-773-702-3163, US"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Rinker-Schaeffer", 
        "givenName": "Carrie", 
        "id": "sg:person.01004114545.00", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01004114545.00"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "Section of Hematology/Oncology, University of Chicago, 5841\u2009S. Maryland, MC2115, Chicago, IL 60637, USA e-mail: wmstadle@mcis.bsd.uchicago.edu Tel.: +1-773-702-4150; Fax: +1-773-702-3163, US"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Stadler", 
        "givenName": "Walter M.", 
        "id": "sg:person.01331545003.30", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01331545003.30"
        ], 
        "type": "Person"
      }
    ], 
    "datePublished": "1999-05", 
    "datePublishedReg": "1999-05-01", 
    "description": "PURPOSE: To determine the in vitro effects of flavopiridol on bladder cancer cell lines, immortalized urothelial cell lines, and normal urothelial cells well characterized for defects in p53, pRb, and p16.\nMETHODS: Growth inhibition was assessed via an MTT assay and apoptosis via DAPI nuclear staining. Cell cycle analysis was performed via propidium iodide staining and fluorescent activated cell sorting (FACS). Multidrug-resistant cells were generated by continuous exposure to doxorubicin.\nRESULTS: Growth inhibition was not correlated with inactivation of p53, pRb, or p16. All cells experienced G2/M arrest within 24 h of flavopiridol exposure. Modest apoptosis was observed but required 72 h of continuous drug exposure to become evident. There was no obvious synergistic or antagonistic toxicity when flavopiridol was combined with radiotherapy or cisplatin dosed at the IC50 despite the observation that radiotherapy and flavopiridol led to more profound G2/M arrest than either agent alone. Doxorubicin-resistant cells, demonstrated to overexpress the MDR1 multi-drug-resistance protein were equally as sensitive to flavopiridol as the parental cells.\nCONCLUSIONS: Flavopiridol is a novel cell cycle inhibitor that may be a useful agent in bladder cancers with tumor suppressor gene alterations and/or multidrug resistance.", 
    "genre": "research_article", 
    "id": "sg:pub.10.1007/s002800050948", 
    "inLanguage": [
      "en"
    ], 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1088364", 
        "issn": [
          "0344-5704", 
          "1432-0843"
        ], 
        "name": "Cancer Chemotherapy and Pharmacology", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "1", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "44"
      }
    ], 
    "name": "In vitro evaluation of flavopiridol, a novel cell cycle inhibitor, in bladder cancer", 
    "pagination": "81-87", 
    "productId": [
      {
        "name": "readcube_id", 
        "type": "PropertyValue", 
        "value": [
          "37cdd837472525d6e48e5ab0ebeea4068fb6b7179cb13fec5073a208aa4a5b93"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "10367753"
        ]
      }, 
      {
        "name": "nlm_unique_id", 
        "type": "PropertyValue", 
        "value": [
          "7806519"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s002800050948"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1011712647"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s002800050948", 
      "https://app.dimensions.ai/details/publication/pub.1011712647"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2019-04-10T19:57", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000001_0000000264/records_8681_00000511.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "http://link.springer.com/10.1007%2Fs002800050948"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s002800050948'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s002800050948'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s002800050948'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s002800050948'


 

This table displays all metadata directly associated to this object as RDF triples.

167 TRIPLES      20 PREDICATES      45 URIs      37 LITERALS      25 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s002800050948 schema:about N0f3031838e03409c8563dc6b8cc95dd8
2 N18d503cf1dba445c886b94f0c227c032
3 N5e69382dc60140969e8b2eb9f1da0498
4 N674e558b81de425fb7295300596b0040
5 N67d7db60987846c38ebcc86b1c2a462d
6 N6aca13ce1d0146bead1013c88e620378
7 N6dcc486eae51418b99fb78bd3bc5355b
8 N6f9b4cfe22d64f2d832ec5f458db7b77
9 N8781657c82d64b3e8f671183d319879b
10 Nb336c0653c544b6ab158a31b19d5077a
11 Nb8a7d72cc5164e09bfcaecd1add1ef19
12 Nc146aebfaf9b4c47affeabed7801e9c7
13 Nc1a338da366d401fa79dbdfae7c70eef
14 Nc34d59bf90e24ccbb6a7e21ff0f74046
15 Ndd348624ee2b43c8b9fc0bda4809258c
16 Nf9c0a849395a4c17be1152d6b86f33d3
17 anzsrc-for:06
18 anzsrc-for:0601
19 schema:author N2f3ff7a4168f4c98b0fb6853f5ed244d
20 schema:datePublished 1999-05
21 schema:datePublishedReg 1999-05-01
22 schema:description PURPOSE: To determine the in vitro effects of flavopiridol on bladder cancer cell lines, immortalized urothelial cell lines, and normal urothelial cells well characterized for defects in p53, pRb, and p16. METHODS: Growth inhibition was assessed via an MTT assay and apoptosis via DAPI nuclear staining. Cell cycle analysis was performed via propidium iodide staining and fluorescent activated cell sorting (FACS). Multidrug-resistant cells were generated by continuous exposure to doxorubicin. RESULTS: Growth inhibition was not correlated with inactivation of p53, pRb, or p16. All cells experienced G2/M arrest within 24 h of flavopiridol exposure. Modest apoptosis was observed but required 72 h of continuous drug exposure to become evident. There was no obvious synergistic or antagonistic toxicity when flavopiridol was combined with radiotherapy or cisplatin dosed at the IC50 despite the observation that radiotherapy and flavopiridol led to more profound G2/M arrest than either agent alone. Doxorubicin-resistant cells, demonstrated to overexpress the MDR1 multi-drug-resistance protein were equally as sensitive to flavopiridol as the parental cells. CONCLUSIONS: Flavopiridol is a novel cell cycle inhibitor that may be a useful agent in bladder cancers with tumor suppressor gene alterations and/or multidrug resistance.
23 schema:genre research_article
24 schema:inLanguage en
25 schema:isAccessibleForFree false
26 schema:isPartOf Nbb22fe3489e24c9fa9c51bbfe8cef259
27 Nf1bfbc0ddb734cfebfab49ac8d455f84
28 sg:journal.1088364
29 schema:name In vitro evaluation of flavopiridol, a novel cell cycle inhibitor, in bladder cancer
30 schema:pagination 81-87
31 schema:productId N29860197106c4e94b408e8bc96275d4c
32 Na3d87e580c2640a3a6326b4add2f0263
33 Nbe3d3d7841fc427c9b34b6b295e160b9
34 Nf9ea97351ac44482a97eff87857a4a17
35 Nfcf83885e73e46b4a781f22067949025
36 schema:sameAs https://app.dimensions.ai/details/publication/pub.1011712647
37 https://doi.org/10.1007/s002800050948
38 schema:sdDatePublished 2019-04-10T19:57
39 schema:sdLicense https://scigraph.springernature.com/explorer/license/
40 schema:sdPublisher N4f29e6611cfd433989cce2064f0d2521
41 schema:url http://link.springer.com/10.1007%2Fs002800050948
42 sgo:license sg:explorer/license/
43 sgo:sdDataset articles
44 rdf:type schema:ScholarlyArticle
45 N090a83197e1b46e6ace09194fe546825 schema:name Section of Hematology/Oncology, University of Chicago, 5841 S. Maryland, MC2115, Chicago, IL 60637, USA e-mail: wmstadle@mcis.bsd.uchicago.edu Tel.: +1-773-702-4150; Fax: +1-773-702-3163, US
46 rdf:type schema:Organization
47 N0f3031838e03409c8563dc6b8cc95dd8 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
48 schema:name Piperidines
49 rdf:type schema:DefinedTerm
50 N18d503cf1dba445c886b94f0c227c032 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
51 schema:name Flavonoids
52 rdf:type schema:DefinedTerm
53 N23c16e28c38f4d3da0d73855750442bb rdf:first sg:person.01331545003.30
54 rdf:rest rdf:nil
55 N29860197106c4e94b408e8bc96275d4c schema:name dimensions_id
56 schema:value pub.1011712647
57 rdf:type schema:PropertyValue
58 N2f3ff7a4168f4c98b0fb6853f5ed244d rdf:first sg:person.01167505012.73
59 rdf:rest N9453fe2cbaec48f19e402226a721095c
60 N4f29e6611cfd433989cce2064f0d2521 schema:name Springer Nature - SN SciGraph project
61 rdf:type schema:Organization
62 N51fb7c44a1ec4cbca59ee3e16f184afa rdf:first sg:person.01106365337.15
63 rdf:rest Na3617e1279ba4e4e9dc5a5a734a30468
64 N5e69382dc60140969e8b2eb9f1da0498 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
65 schema:name Tumor Cells, Cultured
66 rdf:type schema:DefinedTerm
67 N674e558b81de425fb7295300596b0040 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
68 schema:name Drug Resistance, Multiple
69 rdf:type schema:DefinedTerm
70 N67d7db60987846c38ebcc86b1c2a462d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
71 schema:name Combined Modality Therapy
72 rdf:type schema:DefinedTerm
73 N6aca13ce1d0146bead1013c88e620378 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
74 schema:name Cell Cycle
75 rdf:type schema:DefinedTerm
76 N6d521bcddadc4810a38f70fb559f3c31 schema:affiliation N9daa2be2e54f4870a1017824cb186627
77 schema:familyName Astumian
78 schema:givenName Mary
79 rdf:type schema:Person
80 N6dcc486eae51418b99fb78bd3bc5355b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
81 schema:name Cell Line
82 rdf:type schema:DefinedTerm
83 N6f9b4cfe22d64f2d832ec5f458db7b77 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
84 schema:name Humans
85 rdf:type schema:DefinedTerm
86 N8781657c82d64b3e8f671183d319879b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
87 schema:name Urothelium
88 rdf:type schema:DefinedTerm
89 N9453fe2cbaec48f19e402226a721095c rdf:first N6d521bcddadc4810a38f70fb559f3c31
90 rdf:rest N51fb7c44a1ec4cbca59ee3e16f184afa
91 N95c0a1db9520475e92d40dbbca2c3494 schema:name Section of Urology, University of Chicago, Chicago, IL, USA, US
92 rdf:type schema:Organization
93 N9daa2be2e54f4870a1017824cb186627 schema:name Section of Urology, University of Chicago, Chicago, IL, USA, US
94 rdf:type schema:Organization
95 Na3617e1279ba4e4e9dc5a5a734a30468 rdf:first sg:person.01004114545.00
96 rdf:rest N23c16e28c38f4d3da0d73855750442bb
97 Na3d87e580c2640a3a6326b4add2f0263 schema:name pubmed_id
98 schema:value 10367753
99 rdf:type schema:PropertyValue
100 Naafb7100425e499c8d570ccabf1459fd schema:name Section of Hematology/Oncology, University of Chicago, 5841 S. Maryland, MC2115, Chicago, IL 60637, USA e-mail: wmstadle@mcis.bsd.uchicago.edu Tel.: +1-773-702-4150; Fax: +1-773-702-3163, US
101 rdf:type schema:Organization
102 Nb336c0653c544b6ab158a31b19d5077a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
103 schema:name Urinary Bladder Neoplasms
104 rdf:type schema:DefinedTerm
105 Nb8a7d72cc5164e09bfcaecd1add1ef19 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
106 schema:name Apoptosis
107 rdf:type schema:DefinedTerm
108 Nbb22fe3489e24c9fa9c51bbfe8cef259 schema:issueNumber 1
109 rdf:type schema:PublicationIssue
110 Nbe3d3d7841fc427c9b34b6b295e160b9 schema:name nlm_unique_id
111 schema:value 7806519
112 rdf:type schema:PropertyValue
113 Nc146aebfaf9b4c47affeabed7801e9c7 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
114 schema:name Antineoplastic Agents
115 rdf:type schema:DefinedTerm
116 Nc16965e7d7a842e2bb2261833bb6bd44 schema:name Section of Hematology/Oncology, University of Chicago, 5841 S. Maryland, MC2115, Chicago, IL 60637, USA e-mail: wmstadle@mcis.bsd.uchicago.edu Tel.: +1-773-702-4150; Fax: +1-773-702-3163, US
117 rdf:type schema:Organization
118 Nc1a338da366d401fa79dbdfae7c70eef schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
119 schema:name Genes, Tumor Suppressor
120 rdf:type schema:DefinedTerm
121 Nc34d59bf90e24ccbb6a7e21ff0f74046 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
122 schema:name Cell Division
123 rdf:type schema:DefinedTerm
124 Ndd348624ee2b43c8b9fc0bda4809258c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
125 schema:name Cisplatin
126 rdf:type schema:DefinedTerm
127 Nf1bfbc0ddb734cfebfab49ac8d455f84 schema:volumeNumber 44
128 rdf:type schema:PublicationVolume
129 Nf9c0a849395a4c17be1152d6b86f33d3 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
130 schema:name Radiotherapy
131 rdf:type schema:DefinedTerm
132 Nf9ea97351ac44482a97eff87857a4a17 schema:name readcube_id
133 schema:value 37cdd837472525d6e48e5ab0ebeea4068fb6b7179cb13fec5073a208aa4a5b93
134 rdf:type schema:PropertyValue
135 Nfcf83885e73e46b4a781f22067949025 schema:name doi
136 schema:value 10.1007/s002800050948
137 rdf:type schema:PropertyValue
138 anzsrc-for:06 schema:inDefinedTermSet anzsrc-for:
139 schema:name Biological Sciences
140 rdf:type schema:DefinedTerm
141 anzsrc-for:0601 schema:inDefinedTermSet anzsrc-for:
142 schema:name Biochemistry and Cell Biology
143 rdf:type schema:DefinedTerm
144 sg:journal.1088364 schema:issn 0344-5704
145 1432-0843
146 schema:name Cancer Chemotherapy and Pharmacology
147 rdf:type schema:Periodical
148 sg:person.01004114545.00 schema:affiliation Naafb7100425e499c8d570ccabf1459fd
149 schema:familyName Rinker-Schaeffer
150 schema:givenName Carrie
151 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01004114545.00
152 rdf:type schema:Person
153 sg:person.01106365337.15 schema:affiliation Nc16965e7d7a842e2bb2261833bb6bd44
154 schema:familyName Liebowitz
155 schema:givenName David
156 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01106365337.15
157 rdf:type schema:Person
158 sg:person.01167505012.73 schema:affiliation N95c0a1db9520475e92d40dbbca2c3494
159 schema:familyName Chien
160 schema:givenName Mark
161 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01167505012.73
162 rdf:type schema:Person
163 sg:person.01331545003.30 schema:affiliation N090a83197e1b46e6ace09194fe546825
164 schema:familyName Stadler
165 schema:givenName Walter M.
166 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01331545003.30
167 rdf:type schema:Person
 




Preview window. Press ESC to close (or click here)


...